SCHEMBL3582937

SCHEMBL3582937

CS(=O)(=O)c1cc([N+](=O)[O-])c(C(=O)NCCO)cc1N(CCBr)CCBr

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.38
CYP3A4 P08684 1/20 0.38
THRA P10827 9/20 0.38
VDR P11473 4/20 0.38
THRB P10828 7/20 0.38
CA12 O43570 2/20 0.37
CA1 P00915 2/20 0.37
CA2 P00918 2/20 0.37
CA3 P07451 2/20 0.37
CA4 P22748 2/20 0.37
CA6 P23280 2/20 0.37
CA5A P35218 2/20 0.37
CA7 P43166 2/20 0.37
CA9 Q16790 2/20 0.37
CA13 Q8N1Q1 2/20 0.37
CA14 Q9ULX7 2/20 0.37
CA5B Q9Y2D0 2/20 0.37
POLB P06746 1/20 0.35
PRMT5 O14744 1/20 0.35
WDR77 Q9BQA1 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15574179 0.94 THRA (0.40) NPC1CYP3A4THRAVDRTHRB
SCHEMBL15574355 0.91 ALDH1A1 (0.40) NPC1CYP3A4THRAVDRTHRB
SCHEMBL15573232 0.91 SMN1; SMN2 (0.41) NPC1CYP3A4THRAVDRTHRB
SCHEMBL15574831 0.90 THRA (0.43) NPC1CYP3A4THRAVDRTHRB
SCHEMBL15572713 0.90 NPC1 (0.38) NPC1CYP3A4THRAVDRTHRB
SCHEMBL18506059 0.89 THRA (0.38) NPC1CYP3A4THRAVDRTHRB
SCHEMBL15574585 0.88 NPC1 (0.40) NPC1CYP3A4THRAVDRTHRB
SCHEMBL15573697 0.88 THRA (0.44) NPC1CYP3A4THRAVDRTHRB
SCHEMBL15573655 0.87 NPC1 (0.39) NPC1CYP3A4THRAVDRTHRB
SCHEMBL17180950 0.87 THRA (0.37) NPC1CYP3A4THRAVDRTHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150299230-A1 Novel Prodrugs And Methods Of Use Thereof Convert Pharmaceuticals SA (BE) 2015-10-22 US claimed
EP-2888227-A1 NOVEL PRODRUGS AND METHODS OF USE THEREOF Auckland Uniservices Limited (NZ) 2015-07-01 EP claimed
WO-2014031012-A1 NOVEL PRODRUGS AND METHODS OF USE THEREOF AUCKLAND UNISERVICES LIMITED (NZ) 2014-02-27 WO claimed
US-20100010094-A1 Novel nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic agents AUCKLAND UNISERVICES LIMITED (NZ) 2010-01-14 US claimed
US-20070032455-A1 Novel nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic agents AUCKLAND UNIVERVICES LIMITED (NZ) 2007-02-08 US claimed
EP-2888227-B1 NOVEL PRODRUGS AND METHODS OF USE THEREOF Convert Pharmaceuticals SA (BE) 2020-07-29 EP disclosed
US-20190153002-A1 Novel Prodrugs And Methods Of Use Thereof Convert Pharmaceuticals SA (BE) 2019-05-23 US disclosed
US-10202408-B2 Prodrugs and methods of use thereof HEALTH INNOVATION VENTURES B.V. (NL) 2019-02-12 US disclosed
US-20180148463-A1 Novel Prodrugs And Methods Of Use Thereof Convert Pharmaceuticals SA (BE) 2018-05-31 US disclosed
US-9873710-B2 Prodrugs and methods of use thereof HEALTH INNOVATION VENTURES B.V. (NL) 2018-01-23 US disclosed
US-20170044191-A1 Novel Prodrugs And Methods Of Use Thereof Convert Pharmaceuticals SA (BE) 2017-02-16 US disclosed
US-20170044191-A1 Novel Prodrugs And Methods Of Use Thereof Convert Pharmaceuticals SA (BE) 2017-02-16 US disclosed
US-20100010094-A1 Novel nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic agents AUCKLAND UNISERVICES LIMITED (NZ) 2010-01-14 US disclosed
US-7629332-B2 Nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic agents AUCKLAND UNISERVICES LIMITED (NZ) 2009-12-08 US disclosed
US-7629332-B2 Nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic agents AUCKLAND UNISERVICES LIMITED (NZ) 2009-12-08 US disclosed
US-20070032455-A1 Novel nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic agents AUCKLAND UNIVERVICES LIMITED (NZ) 2007-02-08 US disclosed
US-20070032455-A1 Novel nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic agents AUCKLAND UNIVERVICES LIMITED (NZ) 2007-02-08 US disclosed
EP-1680394-A4 NOVEL NITROPHENYL MUSTARD AND NITROPHENYLAZIRIDINE ALCOHOLS AND THEIR CORRESPONDING PHOSPHATES AND THEIR USE AS TARGETED CYTOTOXIC AGENTS AUCKLAND UNISERVICES LTD (NZ) 2006-10-11 EP disclosed
EP-1680394-A1 NOVEL NITROPHENYL MUSTARD AND NITROPHENYLAZIRIDINE ALCOHOLS AND THEIR CORRESPONDING PHOSPHATES AND THEIR USE AS TARGETED CYTOTOXIC AGENTS Auckland Uniservices Limited (NZ) 2006-07-19 EP disclosed
WO-2005042471-A1 NOVEL NITROPHENYL MUSTARD AND NITROPHENYLAZIRIDINE ALCOHOLS AND THEIR CORRESPONDING PHOSPHATES AND THEIR USE AS TARGETED CYTOTOXIC AGENTS AUCKLAND UNISERVICES LIMITED (NZ) 2005-05-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180148463-A1 Novel Prodrugs And Methods Of Use Thereof AKR1C3, AKR1C2, AKR1B1 NPC1 998/4885CYP3A4 498/4885THRA 2653/4885
US-20190153002-A1 Novel Prodrugs And Methods Of Use Thereof AKR1C3, AKR1C2, AKR1B1 NPC1 998/4885CYP3A4 498/4885THRA 2653/4885
US-20150299230-A1 Novel Prodrugs And Methods Of Use Thereof AKR1C3, AKR1C2, AKR1B1 NPC1 998/4885CYP3A4 498/4885THRA 2653/4885
US-20070032455-A1 Novel nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic agents NAPRT, NTPCR, PNP NPC1 1359/4885CYP3A4 477/4885THRA 3130/4885
US-10202408-B2 Prodrugs and methods of use thereof AKR1C3, AKR1C2, AKR1C1 NPC1 1040/4885CYP3A4 227/4885THRA 2773/4885
US-20100010094-A1 Novel nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic agents NAPRT, NTPCR, QDPR NPC1 1461/4885CYP3A4 588/4885THRA 3012/4885
US-20170044191-A1 Novel Prodrugs And Methods Of Use Thereof AKR1C3, AKR1C2, AKR1B1 NPC1 998/4885CYP3A4 498/4885THRA 2653/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.